Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Glucotrack (Nasdaq:GCTK) announced today that it received a hospital's ethical approval to study its continuous blood glucose ...

Ken Griffin, the founder of Citadel, is an influential albeit controversial figure in the investment industry.

Dexcom (Nasdaq:DXCM) announced today that it promoted Jake Leach to the role of president, in addition to his post as COO.

The smaller Mobi pump for more active users was launched in 2024, and the Sigi patch pump is in development. With this range of products, we think it’s likely Tandem can address a wider swath of both ...

DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins. Check out why I am lowering my rating on DXCM from buy to hold.

DexCom, Inc. (NASDAQ: DXCM) has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) ...